Encephalitis, Tick-Borne Clinical Trial
Official title:
Fever After Tick Bite (FATB) Study; Determining the Etiology of Tick-Borne Human Infections in Northern Europe
The proposed study is a collaboration between Microbiology, SU/Sahlgrenska and the Infectious
Diseases clinic at SU/Östra as well as several Infectious Diseases clinics throughout Sweden
aiming at improving microbiological diagnostic assays regarding the early identification of
tick-borne microorganisms (including as of yet unidentified pathogens) capable of causing
human disease using modern diagnostic tools.
At the initial study visit (day 0) plasma, serum, urine, saliva, and PBMCs (and tick, if
available) will be collected from patients developing fever within two weeks after a tick
bite. Additional follow-up samples will be obtained after 9 and 30 days as well as after 6
months. The initial samples will be analyzed using (a) directed multiplex PCR analysis for
Tick-Borne Encephalitis (TBE), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella,
Tularemia, and Babesiosis in plasma, whole blood and urine, (b) conventional IgM and IgG
serology for TBE, (c) "Next Generation Sequencing" (NGS) for the detection of bacterial 16s
rRNA as well as unknown viruses, (d) potential biomarkers, and (e) host genetic factors.
Among patients where initial sampling indicates the presence of a potential pathogen or in
patients developing neurological symptoms, a lumbar puncture will be performed and CSF will
be further analyzed. Samples will also be evaluated regarding potential microbiological
factors predisposing for severity of infection.
The primary objective of the study is to improve diagnostic tools in the initial early phase
of infections caused by tick-borne pathogens, especially TBE prior to the affliction of the
central nervous system, and to attempt to identify which factors impact the course of
infection as it is believed that approximately 75% of infected individuals resolve their
infection in this first phase whereas others develop meningoencephalitis with significant
subsequent neurological sequelae. Secondary objectives of the study include investigating for
the presence of and treating other tick-borne pathogens, setting the stage for coming
clinical trials evaluating novel anti-viral therapies for TBE.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01031537 -
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
|
Phase 2 | |
| Completed |
NCT00460486 -
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
|
Phase 3 | |
| Completed |
NCT00161824 -
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
|
Phase 3 | |
| Completed |
NCT00163540 -
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
|
Phase 4 | |
| Completed |
NCT00161967 -
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
|
Phase 4 | |
| Completed |
NCT00161876 -
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
|
Phase 3 | |
| Completed |
NCT00311441 -
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
|
Phase 4 | |
| Completed |
NCT00161954 -
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
|
Phase 4 | |
| Completed |
NCT00163618 -
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
|
Phase 4 | |
| Completed |
NCT00503529 -
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
|
Phase 4 | |
| Completed |
NCT00840801 -
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
|
Phase 3 | |
| Completed |
NCT00452621 -
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
|
Phase 4 | |
| Completed |
NCT00311493 -
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
|
Phase 4 | |
| Completed |
NCT00161889 -
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
|
Phase 2 | |
| Completed |
NCT00161850 -
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
|
Phase 2 | |
| Completed |
NCT00894686 -
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
|
Phase 4 | |
| Completed |
NCT00161746 -
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
|
Phase 2/Phase 3 |